OR WAIT null SECS
Optibrium, software developer for drug discovery, has raised investment from Kester Capital, a private equity firm, for the development of its business.
Optibrium, software developer for drug discovery, has raised investment from Kester Capital, a private equity firm, for the development of its business. The investment was announced in a Feb 10, 2021 press release.
Using the funds received from Kester Capital, Optibrium will drive commercial growth and develop new products for the improvement of speed, efficiency, and productivity of drug discovery. Lead products for Optibrium include StarDrop and Cerella. StarDrop is a suite of integrated software for small molecule design, optimization, and data analysis, and the Cerella platform delivers artificial intelligence technology that learns from complex drug discovery data to target high-potential chemical compounds.
“Optibrium is a cutting-edge software business that is driving some of the most exciting developments within computer-aided drug discovery,” said Adam Maidment, managing partner of Kester Capital, in the press release. “We had been tracking the business for some time and were really impressed by the team and the business’ achievements.”
Matt Segall, CEO of Optibrium, added in the press release, “We are delighted to have Kester Capital on board as an investment partner to continue the successful evolution of the business. Kester has extensive experience in the life sciences sector, and we are looking forward to working with them to capitalize on the substantial market opportunities.”